Steven H. Holtzman is a founder, and served as Infinity's Chief Executive Officer from the Company's inception through the end of 2009. From early 1994 through mid 2001, Mr. Holtzman served as the Chief Business Officer of Millennium Pharmaceuticals. In this role, at various times he had management responsibility for the Company's activities in the areas of: business development, M&A, licensing, intellectual property and corporate law, human resources, finance, corporate and government affairs, bioethics, public policy, media relations, investor relations, and corporate communications.
Prior to joining Millennium, from 1986-1994, Mr. Holtzman was a founder, the first employee, and Executive Vice President of DNX Corporation, the first commercial enterprise devoted to the development of agricultural, biomedical, and pharmaceutical applications of transgenic animal technology. Prior to DNX, in the early 1980's, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation's first state government program directed to achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. In the late 1970's, Mr. Holtzman was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K.
Mr. Holtzman co-founded and from 1995-2000 was the Co-Chair of the Biotechnology Industry Organization (BIO) Bioethics Committee. From 1996-2001, he served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. He is also a Trustee of the Berklee College of Music. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar.
Adelene Q. Perkins is the President and Chief Executive Officer with responsibility for business development,corporate strategy and development, finance, organization development and human resources, IR/PR, legal, and facilities and operations. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as Vice President of Business and Corporate Development and, as an early member of the management team, played an instrumental role in building the company.
Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Wyeth, where she was appointed to the newly formed position of Vice President of Emerging Businesses with a mandate to identify and capitalize on opportunities to form new business ventures. In this role, she co-founded and served as General Manager of the DiscoverEase™ Business Unit where she was responsible for building and managing an operating unit that generated a library of over 800 novel genes that encode for secreted proteins which was partnered with over 50 corporate and academic partners. She also formed and served as CEO of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University directed at discovering and developing members of the TGF-b superfamily. She initially joined Genetics Institute in Corporate and Business Development where she led corporate and product strategy initiatives and was responsible for numerous business development transactions both in- and out-licensing technologies and products.
From 1985-1992, Ms. Perkins was at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry. She managed Bain's internal strategy initiative which identified the need for industry practice areas, including the formation of the firm's healthcare practice.
Ms. Perkins holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from Villanova University.
Martin Babler, Chair of Infinity's Compensation Committee, is Chief Executive Officer of Talima Therapeutics, Inc., a privately-held drug delivery company, a position he has held since February 2008. Prior to joining Talima, from 2000 to 2006, Mr. Babler was Vice President of Immunology Sales and Marketing, and Director of Cardiovascular Marketing, at Genentech, Inc. Prior to joining Genentech, Mr. Babler held various roles of increasing responsibility in sales, sales management, marketing and business development with Eli Lilly and Company. Mr. Babler holds a degree in Pharmacy/Pharmacology from the ETH in Zurich, Switzerland and has attended the Executive Development Program at Kellogg Graduate School of Management.
Anthony B. Evnin, Ph.D., has served as Managing General Partner of Venrock Associates since 1980. and has been employed by Venrock Associates since 1974. Dr. Evnin also serves as a director of several private companies, as well as the following publicly-traded biopharmaceutical companies: Icagen, Inc.; Memory Pharmaceuticals Corp.; Pharmos Corporation; Renovis, Inc.; Coley Pharmaceuticals, Inc.; and Sunesis Pharmaceuticals, Inc. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
Broad Institute, MIT, Whitehead Institute, Harvard Medical School
Eric S. Lander, Ph.D., was a co-founder of Infinity, and served as a member of its board of directors since 2001. Dr. Lander has been a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology since 1990 and a Professor of Systems Biology at Harvard Medical School since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993 to 2003, Dr. Lander was the Director of the Whitehead/MIT Center for Genome Research. Dr. Lander is a founder and serves as a director of Millennium Pharmaceuticals, Inc., a publicly traded pharmaceutical company. Dr. Lander received an A.B. in Mathematics from Princeton University and a D.Phil. in Mathematics from Oxford University, which he attended as a Rhodes Scholar.
Mr. Patrick Lee, is a General Partner of Ares Life Sciences, an investment firm, since February 2009. Prior to joining Ares Life Science, Mr. Lee was a General Partner of Advent Venture Partners, and had been employed by Advent Venture Partners since 1999. Before Advent Venture Partners, from 1989 to 1999, Mr. Lee held various positions with Rhone-Poulenc Rorer in the U.S., and Rhone Poulenc in Paris, France, where he was most recently Group Vice President for Mergers & Acquisitions. Prior to that he had been with Baxter International and Booz Allen and Hamilton. Mr. Lee received a B.A. in Biology from Vassar College and an M.B.A. from the Stanford Graduate School of Business.
Arnold J. Levine, Ph.D., lead Research & Development Director, is a Professor at The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine and a Professor at the Institute for Advanced Study. From 1998 to 2002, Dr. Levine was President of Rockefeller University. Prior to joining Rockefeller University, Dr. Levine was the Harry C. Weiss Professor in the Life Sciences and Chairman of the Department of Molecular Biology at Princeton University from 1984 to 1996. Dr. Levine also serves as a director of Theravance, Inc., and Applera Corporation, publicly-traded life science companies. Dr. Levine received a B.A. in Biology from Harpur College, State University of New York at Binghamton and a Ph.D. in Microbiology from The University of Pennsylvania.
Thomas J. Lynch, M.D. is the Director of the Yale Cancer Center and the Physician-in-Chief at Smilow Cancer Hospital at Yale-New Haven. He has focused his career on the care and treatment of patients with lung cancer and the clinical development of novel agents targeting lung cancer. Recently, his work has focused on agents directed against the epidermal growth factor receptor (EGFR) and the potential role that EGFR mutations play in lung cancer biology. Prior to 2009, Dr. Lynch was the Chief of Hematology-Oncology at Massachusetts General Hospital (MGH) and a Professor of Medicine at Harvard Medical School. He received his M.D. from Yale University and completed his internship and residency at MGH. Before joining the staff at MGH, Dr. Lynch served as a fellow in medical oncology at the Dana-Farber Cancer Institute. Dr. Lynch is a founding board member and vice chair of the board of the Kenneth B. Schwartz Center, a foundation devoted to promoting compassionate health care.
The Media Lab, Massachusetts Institute of Technology
Frank Moss, Ph.D., was a co-founder of Infinity and served as a member of its board of directors since 2001. Since 1998, Dr. Moss has been President of Strategic Software Ventures, a firm that nurtures enterprise software startup companies, and since February 2006, Dr. Moss has served as Director of The Media Lab and Weisner Professor of Media Arts and Sciences at the Massachusetts Institute of Technology. From 2001 through 2003, Dr. Moss served as Chairman of the Informatics Advisory Board of Old Infinity. From 1991 to 1996, Dr. Moss served as Chief Executive Officer and Chairman of Tivoli Systems, a private software company sold to IBM in 1996. Prior to joining Tivoli Systems, Dr. Moss held a variety of positions with Lotus Development, Stellar Computer, Apollo Computer and IBM Research. Dr. Moss serves as a director of Tenacre Country Day School. Dr. Moss received a B.S. in Aerospace and Mechanical Sciences from Princeton University and a S.M. and Ph.D. in Aeronautics and Astronautics from the Massachusetts Institute of Technology.
Ian F. Smith, Chair of Infinity's Audit Committee, is Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, Inc., a position he has held since February 2006. From November 2003 to February 2006, he was Vertex's Senior Vice President and Chief Financial Officer, and from October 2001 to November 2003, he served as Vertex's Vice President and Chief Financial Officer. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. Mr. Smith initially joined Ernst & Young's U.K. firm in 1987, and then joined its Boston office in 1995. Mr. Smith currently is a member of the Board of Directors of Acorda Therapeutics, Inc., Epix Pharmaceuticals, Inc. and TolerRx Inc., all publicly-traded biopharmaceutical companies. Mr. Smith holds a B.A. in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales.
James B. Tananbaum, M.D., M.B.A., has served as a member of our board of directors since 2001. From 2000 to the present, Dr. Tananbaum has served as a managing director of Prospect Venture Partners II, L.P. and Prospect Venture Partners III, L.P., venture partnerships he co-founded. From 1997 to 2000, Dr. Tananbaum served as Chief Executive Officer of Theravance, Inc., a publicly traded biopharmaceutical company. From 1993 to 1997, Dr. Tananbaum served as a partner of Sierra Ventures, a venture capital firm. Dr. Tananbaum also serves as a director of Jazz Pharmaceuticals, a private biopharmaceutical company, and the following publicly traded biopharmaceutical companies: Critical Therapeutics, Inc., Vanda Pharmaceuticals, Inc. and Novavax, Inc. Dr. Tananbaum received a B.S.E.E. from Yale University and an M.D. and M.B.A. from Harvard University.
Michael C. Venuti, Ph.D., has served as a member of the board of directors of Infinity and DPI since May 2003. Dr. Venuti has been President and Chief Scientific Officer of iPierian, Inc., a privately-held drug discovery company, since February 2010. Prior to that, Dr. Venuti was Chief Executive Officer and a Director of BioSeek, Inc., a privately-held drug discovery company, from November 2007 to February 2010, when it was acquired by Asterand plc. Dr. Venuti was an Operating Manager at TPG Growth Biotech Ventures, a private equity firm, from January through June 2007. Dr. Venuti served as the Acting Chief Executive Officer of DPI prior to the completion of the reverse merger and as its Chief Scientific Officer from April 2005 through September 2006. Prior to that, he was Senior Vice President of Pharmacogenomics, and was named Senior Vice President of Research and General Manager of Celera South San Francisco when the Celera Genomics Group of Applera Corporation, a life sciences company, acquired Axys Pharmaceuticals, Inc. in 2001. From 1994 through 2001, Dr. Venuti was Director of Medicinal Chemistry, and then Chief Technical Officer, for Axys Pharmaceuticals and its predecessor company, Arris Pharmaceutical Corporation. Dr. Venuti has also held an appointment as Adjunct Professor of Chemistry at the University of California, San Francisco since from 1992 through 2009. Dr. Venuti received an A.B. in Chemistry from Dartmouth College and a Ph.D. in Organic Chemistry from the Massachusetts Institute
of Technology.
= Chair of the Board
= Chair
= Member
* = Lead Outside Director
Contact the Board
You can contact our Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.
Board of Directors
Infinity Pharmaceuticals, Inc.
780 Memorial Drive
Cambridge, MA 02139 contactboard@infi.com
617.453.1116
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, Infinity's Board of Directors has requested that certain items which are unrelated to the duties and responsibilities of the Board should be excluded, such as:
Product complaints
Product inquiries
New product suggestions
Resumes and other forms of job inquiries
Surveys
Business solicitations or advertisements
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
President and Chief Executive Officer
